- Home
- CERT vs XNCR Comparison
CERT vs XNCR Comparison
Compare CERT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERT | XNCR |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.9M | 881.9M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CERT | XNCR |
|---|---|---|
| Price | $5.90 | $11.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $11.67 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 3.5M | 648.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | $125,576,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $5.39 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.75 | ★ 13.65 |
| 52 Week Low | $4.45 | $6.92 |
| 52 Week High | $13.88 | $18.69 |
Technical Indicators
Market Signals| Indicator | CERT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 49.68 |
| Support Level | $5.19 | $10.83 |
| Resistance Level | $6.47 | $12.87 |
| Average True Range (ATR) | 0.36 | 0.58 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 88.68 | 49.60 |
Price Performance
Historical ComparisonAbout CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.